Navigation Links
Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
Date:11/23/2009

nical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.


CONTACT: Amgen, Thousand Oaks
Mary Klem: (805) 447-6979 (media)
John Shutter: (805) 447-1060 (investors)

(Logo: '/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
10. Call for Applications: The Amgen Award for Science Teaching Excellence
11. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... July 12, 2014 Demand Response Management ... considerable benefits in reducing the imbalance between energy supply ... appliances have been rolled out (due to increasing pressure ... (AMI). This helps in controlling residential appliances and thermostats ... in the North American region, and with government mandates ...
(Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... 12, 2014 “Critical Care Therapeutics ... and Late-Stage Four-Factor PCCs and Recombinant Products to ... critical care market in the US, UK, France, ... provides an estimation of market size for 2013, ... critical care indications that are being treated using ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... as 10-fold, researchers find, , MONDAY, Sept. 7 (HealthDay ... minor infection can double the rate of memory loss, ... found that Alzheimer,s patients who had respiratory, gastrointestinal or ... can have high levels of tumor necrosis factor-alpha (TNF-a), ...
... minor complications seen with ,after-hours, procedures, study finds , ... daytime slot to undergo an orthopedic procedure may lower ... a new study has found. , The study, ... of Bone and Joint Surgery , found little difference ...
... 7 Bounty, the UK,s favourite parenting,club, today launches a 4 ... mums take a real life, close up peek at how a ... To view the Multimedia News Release, please click: , ... Breastfeeding is the healthiest and most natural way to feed a ...
... , , , ... Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell ... its breakthrough stem cell and related technology. The Jordanian Stem ... purchase the technology from Stemedica,s wholly-owned subsidiary, Stemedica International, S.A. ...
... in clearance of amyloid plaque from brain , SUNDAY, ... scientists have uncovered three gene variants that up the ... dementia among the elderly and the seventh-leading cause of ... Dr. Philippe Amouyel of the Institut Pasteur de Lille ...
... ... the grand opening of the new rehabilitation hospital with partner HealthSouth. , ... Mesa, Ariz. (PRWEB) September 6, ... on August 18 to welcome the rehabilitation hospital to the East Valley and ...
Cached Medicine News:Health News:Even Mild Infections Hasten Decline With Alzheimer's 2Health News:Even Mild Infections Hasten Decline With Alzheimer's 3Health News:Let Orthopedic Surgery Wait Until Morning When Possible 2Health News:Bounty Parenting Club Launches View on Demand 'How to Breastfeed' Video 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 2Health News:The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. 3Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 2Health News:Trio of Gene Variants Discovered That May Raise Alzheimer's Risk 3Health News:ATSU Arizona Health & Technology Park Partner HealthSouth Holds Grand Opening 2
... Pro Osteon Bone Graft Substitutes a natural ... from cadaver bone, but such grafts may ... disease transmission. Interpore Cross has developed the ... to address these needs, offering surgeons a ...
... Healos is an osteoconductive matrix constructed ... fully coated with hydroxyapatite through a ... with autogenous bone marrow aspirate, Healos ... cell attachment, proliferation and differentiation. The ...
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Sharp Weitlaner Retractor....
Medicine Products: